Phase 2 Readout
Phase 2 Readout: nxc-201
- Company
- Immix Biopharma, Inc. (IMMX)
- Drug
- nxc-201
- Indication
- relapsed/refractory AL Amyloidosis
Other upcoming events for IMMX
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.